Application of sodium-glucose co-transporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for patients with type 2 diabetes mellitus and cardiovascular diseases of atherosclerotic genesis in clinical practice

Abstract

The discovery of two new classes of antidiabetic drugs: SGLT-2 inhibitors and GLP-1 receptor agonists has made a breakthrough in medication for patients with type 2 diabetes mellitus, but also for patients with cardiovascular diseases (including atherosclerosis). Combination of these two pathologies is often found in cardiological practice. However, we should mention that these drugs have proven efficacy in course and outcomes of cardiovascular diseases despite the diagnosis of diabetes mellitus. Patients with type 2 diabetes mellitus and cardiovascular diseases have extremely high risk of fatal and non-fatal cardiovascular complications, so it’s quite important to introduce new pharmacotherapy treatment into the daily practice of cardiologist. However, the awareness of the necessity and right to appoint these drugs of cardiologists in Russian Federation is still not enough nowadays.